ReCode Therapeutics, 1140 O'Brien Drive, Menlo Park, CA (2025)

09/12/2025

Congratulations to ReCode Scientific Advisory Board (SAB) member Dr. Eric Olson, Ph.D., on being awarded the 2025 Louisa Gross Horwitz Prize from University. This prestigious honor recognizes his pioneering research in muscle biology and genetic medicine, advancing the understanding of Duchenne muscular dystrophy (DMD) and laying the groundwork for new therapeutic approaches for patients.

Dr. Olson’s scientific leadership continues to inspire the field of genetic medicine and accelerate progress in rare diseases. We are grateful for his guidance as a member of our SAB, where his expertise helps inform our work on our Cystic Fibrosis program and advance our mission to deliver new possibilities for patients with rare diseases.

09/08/2025

Did you know that about 10% of people with cystic fibrosis have genetic changes that current treatments can’t address? These specific changes prevent the production of the CFTR protein, which is essential for current therapies to work. We’re working on an investigational therapy designed to help this group within the CF community.

Learn more about the RCT2100 clinical study and our investigational therapy via the link in our bio.

09/04/2025

Yesterday in New York City, our CEO Shehnaaz Suliman moderated “Perspectives on Navigating Uncertainty at the FDA” at the Biotech CEO Sisterhood Forum hosted by J.P. Morgan.

With:
Julie Tierney — Leavitt Partners
Brad Zakes — Biotechnology Innovation Organization (BIO)
Jevan Jammal — No Patient Left Behind
Emily Minkow — RA Capital Management

This conversation brought together leaders from across the industry to examine how policy, science, and patient needs intersect, and how companies can navigate this landscape to bring innovative therapies to patients faster and responsibly.

We’re grateful to J.P. Morgan and the Biotech CEO Sisterhood for creating a forum for these important discussions, and to the fellow panelists who brought their thoughtful insights and perspectives.

09/01/2025

This Labor Day, we recognize the people whose work powers progress. From the labs advancing breakthrough science to the many roles that make innovation possible. Biotechnology thrives on collaboration and resilience. Every discovery and advancement reflects shared effort and commitment.

Labor Day is also a reminder of our responsibility to create a workplace where every perspective matters, every voice is heard, and opportunity is accessible to all. At ReCode, this shapes how we work each day, because science advances when inclusion is part of the design.

Here’s to the people driving impact today and shaping a healthier tomorrow. And here’s to weathering extraordinary headwinds and staying the course to make the difference we all hope to make!

08/18/2025

About 10% of the CF community has genetic mutations that do not benefit from existing therapeutics. Despite the availability of CFTR modulators that work for 90% of people with cystic fibrosis, many will not be able to take the medication due to side effects, lack of response, or other reasons.

Learn more about a clinical study investigating a treatment for this 10% of people with CF via the link in our bio.

08/12/2025

Cystic fibrosis impacts more than 105,000 people globally, with symptoms affecting multiple organs, especially the lungs. ReCode Therapeutics is committed to changing this outlook with new investigational treatments that address CF at its core. Every trial brings us closer to a future with new hope for the CF community.

For more information about a clinical trial studying an investigational therapy for CF, visit: Cf-clinical-studies.com

08/11/2025

At ReCode Therapeutics, we’re utilizing our SORT LNP platform to deliver inhaled mRNA directly to targeted cells in the lungs. By focusing on specific mutations, our approach is designed to address conditions like cystic fibrosis at the genetic level, a promising direction for people with CF who don’t respond to current treatments.

Clinical trial info in bio.

08/08/2025

Last weekend, the ReCode team joined the .curecf Cystic Fibrosis Research Institute (CFRI) at its 38th National CF Education Conference in Mountain View, CA.

Jessica Couch, Head of Early Development at ReCode, and Priya Ryali, Head of Clinical Operations, spoke about our mission to support the CF community—including the approximately 10% of people who do not benefit from currently approved therapies. This unmet need informs our research and development efforts to explore new options for these individuals.

As a sponsor of this year’s event, we had the opportunity to connect with individuals, caregivers, and researchers who share this commitment. The conference featured discussions on topics such as mRNA and gene therapy, aging with CF, mental health, and health equity—conversations that reflect the collective goal of advancing care for everyone affected by CF.

Special thanks to CFRI for creating a forum that fosters collaboration and progress—and our colleagues Andrew Kriozere, Amanda Chanda, and Alma Araneta from Clinical Operations for representing Team ReCode alongside us.

07/14/2025

Clinical research for cystic fibrosis depends on the strength of the CF community. Every participant, caregiver, and healthcare provider plays a role in moving us forward. ReCode’s clinical study of an inhaled mRNA therapy is an opportunity to stand together in the fight against CF and build a brighter future for everyone affected.

Learn more about our study at https://cf-clinical-studies.com

07/04/2025

Independence Day is a reminder of the responsibility that comes with freedom: the responsibility to think critically, to act with purpose, and to build systems that serve more people equitably.

At ReCode, we see that responsibility in the work we do every day. The ability to ask new questions, to follow the science, and to push for better treatments is only possible in an environment where ideas are allowed to grow and where progress has the potential to reach more people.

Today, we reflect on that freedom and what it demands of us.

Happy Fourth of July.

07/02/2025

As a caregiver, understanding the symptoms of cystic fibrosis can make a world of difference in managing your loved one’s health. Persistent cough, frequent infections, and wheezing are among the signs to watch for.

ReCode’s clinical study of an inhaled mRNA therapy is focused on addressing CF symptoms at their source.

06/26/2025

Cystic fibrosis impacts more than 105,000 people globally, with symptoms affecting multiple organs, especially the lungs. ReCode Therapeutics is committed to changing this outlook with new investigational treatments that address CF at its core. Every trial brings us closer to a future with new hope for the CF community.

ReCode Therapeutics

09/12/2025

09/08/2025

09/04/2025

09/01/2025

08/18/2025

08/12/2025

08/11/2025

08/08/2025

07/14/2025

07/04/2025

07/02/2025

06/26/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category